Clinical trial NCT03818854: Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome
Official title: A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells (hMSCs) for the Treatment of Acute Respiratory Distress Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Respiratory Distress Syndrome, Adult
Keywords: Human Mesenchymal Stromal Cells
Acute Respiratory Distress Syndrome
Lead sponsor: University of California, San Francisco
Sponsor class: OTHER
Collaborators: name: United States Department of Defense
name: Harborview Injury Prevention and Research Center
name: Oregon Health and Science University
name: Vanderbilt University Medical Center
name: The University of Texas Health Science Center, Houston
name: University of Minnesota
First posted: 2019-01-28
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: For this Phase 2b trial, after informed consent is given, an assignment will be made by computer-generated randomization to administer either hMSCs therapy or placebo with a 1:1 allocation to the hMSCs:placebo arms.
Primary purpose: TREATMENT

Brief summary: This is a Phase 2b, randomized, double-blind, placebo-controlled, multi-center study to assess the safety and efficacy of a single dose of Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells (hMSCs) infusion in patients with Acute Respiratory Distress Syndrome (ARDS). This study is the extension of the Phase 1 pilot study (NCT01775774) and Phase 2a study (NCT02097641).

Detailed description: This clinical study design is a randomized, double-blinded, placebo-controlled Phase 2b clinical trial using a 10 million cell/kg dose of human Mesenchymal Stromal Cells (hMSCs). Subjects will be randomized in a 1:1 randomization scheme to receive hMSCs or cell reconstitution media (1:1 mix of 5% human serum albumin and 10% Dextran 40) as the placebo; the study will enroll 120 patients who achieve a stable clinical baseline and receive study product (either hMSCs or the placebo).

The Data and Safety Monitoring Board (DSMB) will review adverse outcomes and protocol compliance. A pre-specified interim review will occur after 60 subjects have been enrolled and received study product; enrollment will continue during the DSMB review. All pre-specified clinically important events and unexpected serious adverse events including death during hospitalization up to 60 days will be reported to the DSMB on an ongoing basis; the study will be stopped for a safety evaluation by the DSMB if they have any concerns or if three subjects have pre-specified clinically important events or unexpected serious adverse events except death since death will be common in this critically ill population due the nature of the underlying illness (e.g., ARDS).

Eligibility criteria: Inclusion Criteria:

Patients will be eligible for inclusion if they meet all of the below criteria within 14 days of initial ICU admission. Criteria 1-3 must all be present within a 24-hour time period and at the time of enrollment:

Acute onset (defined below) of:

1. A need for positive pressure ventilation by an endotracheal or tracheal tube with a PaO2/FiO2 ratio \<250 mmHg and ≥5 cm H2O positive end-expiratory airway pressure (PEEP), as per the Berlin Criteria.
2. Bilateral infiltrates consistent with pulmonary edema (defined below) on the frontal chest radiograph, or bilateral ground glass opacities on a chest CT scan.
3. No clinical evidence of left atrial hypertension as a primary explanation for the bilateral pulmonary infiltrates.
4. If the cause of ARDS is trauma, additional inclusion criteria will include ONE of the following relevant risk factors for developing ARDS:

   1. Hypotension (systolic blood pressure\[SBP\] \< 90 mmHg) in the field or in the first 24 h after injury, or
   2. Transfusion of 3 units of blood products in the first 24 hours following injury, or
   3. Meets the new Critical Administration Threshold (CAT) criteria with at least 3 units of blood in one hour, or
   4. Blunt or penetrating torso trauma, or
   5. Long bone fractures, or
   6. The highest level of institutional trauma activation

Exclusion Criteria:

1. Age less than 18 years
2. Greater than 72 hours since first meeting ARDS criteria per the Berlin definition of ARDS
3. Greater than 14 days since initial ICU admission
4. Inability to administer study product within 14 days of ICU admission
5. PaO2/FiO2 ≥ 250 mmHg after consent obtained and before study product is administered
6. Unable to obtain informed consent/no surrogate available
7. Pregnant or lactating
8. In custody of law enforcement officials
9. Burns \> 20% of total body surface area
10. WHO Class III or IV pulmonary hypertension
11. History of cancer treatment in the last 2 years except for non-melanotic skin cancers
12. Underlying medical condition for which 6-month mortality is estimated to be \> 50%
13. Moribund patient not expected to survive 24 hours
14. Advanced chronic liver disease (Child-Pugh Score \> 12)
15. Severe chronic respiratory disease with the use of home oxygen
16. Severe traumatic brain injury - defined as:

    1. A patient who has undergone intracranial neurosurgical intervention for monitoring or therapy (intracranial pressure monitoring, external ventricular drain, craniotomy), or
    2. Intracranial injury by head CT (does not include patients with minimal subarachnoid injury and/or minor skull fracture), or
    3. Post-resuscitation Glasgow Coma Score (GCS) \< 9 assessed after sedation interruption, or
    4. Non-survivable head injury as assessed by neurosurgery
17. Evidence of anoxic brain injury
18. History of stroke within the last 3 years
19. No intent/unwillingness to follow lung protective ventilation strategy
20. Currently receiving extracorporeal life support (ECLS) or high-frequency oscillatory ventilation (HFOV)
21. Anticipated extubation within 24 hours of enrollment
22. Clinical evidence of left atrial hypertension as measured by a pulmonary arterial wedge pressure \> 18mmHg or left ventricular failure measured by an echocardiogram with a left ventricular ejection fraction less than 40%. Clinical judgement will determine if either of these measurements needs to be carried out.

Primary outcomes:
measure: Change in oxygenation index (OI)
timeFrame: 36 hours
Secondary outcomes:
measure: Acute Lung Injury Score (LIS)
timeFrame: 7 days
measure: Pulmonary Dead Space Fraction
timeFrame: 7 days
measure: Chest radiograph assessment of pulmonary edema (RALE score)
timeFrame: 7 days
measure: Ventilator free-days
timeFrame: 28 days
measure: Duration of assisted ventilation over 28 days
timeFrame: 28 days
measure: Percentage of patients achieving pressure support ventilation for 2 hours
timeFrame: 28 days
measure: Occurrence of Infection
timeFrame: 14 days
measure: Sequential Organ Failure Assessment (SOFA) over 7 days
timeFrame: 7 days
measure: All-cause hospital mortality
timeFrame: 60 days
measure: Glasgow Outcome Score (GCS)
timeFrame: 60 days
measure: Percentage of patients occurred any thromboembolic events
timeFrame: 60 days
measure: Plasma angiopoietin-2
timeFrame: 72 hours
measure: Plasma Receptor for Advanced Glycation Endproducts (RAGE)
timeFrame: 72 hours
measure: Plasma interleukin-6
timeFrame: 72 hours
measure: Plasma interleukin-8
timeFrame: 72 hours
measure: Plasma Soluble tumor necrosis factor 1 (sTNF-1)
timeFrame: 72 hours
measure: Plasma protein C
timeFrame: 72 hours
measure: Plasma lipoxin A4
timeFrame: 72 hours
measure: Plasma Resolvin D1
timeFrame: 72 hours
measure: Plasma angiopoietin-1
timeFrame: 72 hours
measure: Plasma keratinocyte growth factor (KGF)
timeFrame: 72 hours
measure: Urine microalbumin
timeFrame: 48 hours
measure: Total protein in min-bronchoalveolar lavage (mBAL)
timeFrame: 2 days
measure: Tolerability of the hMSCs - incidence of pre-specified infusion-associated events and unexpected severe adverse events
timeFrame: 24 hours
Other outcomes:
Locations:
city: Sacramento
country: United States
facility: University of California Davis Medical Center
state: California
city: San Francisco
country: United States
facility: Zuckerberg San Francisco General Hospital and Trauma Center
state: California
city: San Francisco
country: United States
facility: University of California San Francisco
state: California
city: Portland
country: United States
facility: Oregon Health & Science University
state: Oregon
city: Nashville
country: United States
facility: Vanderbilt University Medical Center
state: Tennessee
city: Houston
country: United States
facility: Memorial Hermann Hospital - Texas Medical Center
state: Texas
city: Seattle
country: United States
facility: Harborview Medical Center
state: Washington
Study officials:
affiliation: University of California, San Francisco
name: Michael Matthay, MD
role: PRINCIPAL_INVESTIGATOR
References: